ES2182133T3 - Composiciones farmaceuticas para liofilizar. - Google Patents

Composiciones farmaceuticas para liofilizar.

Info

Publication number
ES2182133T3
ES2182133T3 ES97950542T ES97950542T ES2182133T3 ES 2182133 T3 ES2182133 T3 ES 2182133T3 ES 97950542 T ES97950542 T ES 97950542T ES 97950542 T ES97950542 T ES 97950542T ES 2182133 T3 ES2182133 T3 ES 2182133T3
Authority
ES
Spain
Prior art keywords
liofilize
pharmaceutical compositions
polyol
mannitol
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97950542T
Other languages
English (en)
Spanish (es)
Inventor
Chris Bland
Gerald Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Application granted granted Critical
Publication of ES2182133T3 publication Critical patent/ES2182133T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES97950542T 1996-12-20 1997-12-11 Composiciones farmaceuticas para liofilizar. Expired - Lifetime ES2182133T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ES2182133T3 true ES2182133T3 (es) 2003-03-01

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97950542T Expired - Lifetime ES2182133T3 (es) 1996-12-20 1997-12-11 Composiciones farmaceuticas para liofilizar.

Country Status (35)

Country Link
US (1) US6114313A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1007094B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4488538B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100552880B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1121875C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR010377A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE221787T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU758857B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9713974B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2275153C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ300635B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69714616T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1007094T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03857B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2182133T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR15C0060I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU226616B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID21635A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL130449A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS1897B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY121982A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO327142B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ336027A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL190493B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1007094E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2205012C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA97180719B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE9604795D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1007094T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK283137B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199901412T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW522015B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA66779C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1998028009A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA9711055B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2778880C (en) 2009-11-11 2018-02-13 The Medicines Company Methods of treating or preventing stent thrombosis
JP5947316B2 (ja) 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
CN115120606A (zh) 2013-03-09 2022-09-30 奇斯药制品公司 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
MA41326A (fr) * 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
MX2019015448A (es) 2017-06-23 2020-02-19 Chiesi Farm Spa Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Atp凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
CA2155673C (en) * 1993-02-10 2004-08-17 Anthony Howard Ingall N-alkyl-2-substituted atp analogues

Also Published As

Publication number Publication date
CA2275153A1 (en) 1998-07-02
ID21635A (id) 1999-07-08
CZ220199A3 (cs) 1999-11-17
CA2275153C (en) 2008-03-25
AU758857B2 (en) 2003-04-03
NO327142B1 (no) 2009-05-04
RU2205012C2 (ru) 2003-05-27
FR15C0060I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-10-23
EP1007094A1 (en) 2000-06-14
AR010377A1 (es) 2000-06-07
HK1026366A1 (en) 2000-12-15
NO993067L (no) 1999-08-09
ZA9711055B (en) 1998-07-08
TW522015B (en) 2003-03-01
PL190493B1 (pl) 2005-12-30
DE69714616T2 (de) 2003-04-03
SK283137B6 (sk) 2003-03-04
BR9713974B1 (pt) 2010-02-23
NO993067D0 (no) 1999-06-21
IL130449A0 (en) 2000-06-01
HUP0000572A2 (hu) 2001-05-28
DE69714616D1 (de) 2002-09-12
TR199901412T2 (xx) 1999-08-23
US6114313A (en) 2000-09-05
WO1998028009A1 (en) 1998-07-02
IS5064A (is) 1999-06-03
SE9604795D0 (sv) 1996-12-20
CN1240362A (zh) 2000-01-05
IS1897B (is) 2003-10-20
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
SI1007094T1 (en) 2003-02-28
CN1121875C (zh) 2003-09-24
PT1007094E (pt) 2002-12-31
DK1007094T3 (da) 2002-10-28
JP2001507022A (ja) 2001-05-29
SA97180719B1 (ar) 2006-05-13
ATE221787T1 (de) 2002-08-15
JP4488538B2 (ja) 2010-06-23
NZ336027A (en) 2001-03-30
AU5351598A (en) 1998-07-17
HUP0000572A3 (en) 2002-10-28
UA66779C2 (uk) 2004-06-15
EE9900260A (et) 2000-02-15
HU226616B1 (en) 2009-04-28
KR20000069598A (ko) 2000-11-25
EE03857B1 (et) 2002-10-15
BR9713974A (pt) 2000-04-11
CZ300635B6 (cs) 2009-07-08
MY121982A (en) 2006-03-31
FR15C0060I2 (fr) 2016-04-22
PL334006A1 (en) 2000-01-31
EP1007094B1 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
ES2145115T3 (es) Composiciones inyectables a base de derivados de taxanos.
ES2182133T3 (es) Composiciones farmaceuticas para liofilizar.
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
AR012531A1 (es) Composicion para cuidado personal, composicion para repasador y metodo para minimizar o reducir la comezon o quemado de la piel a causa de composicionespara cuidado personal que contienen acido.
HUP9900717A2 (hu) Szilárd dezodoráló készítmény
BR9900320A (pt) Composição antimicrobiana
ES2112140B1 (es) 3-arilbenzofuranonas como estabilizantes
PT966341E (pt) Agente de proteccao da madeira para aplicacao posterior
ATE226240T1 (de) Xanthangummi enthaltende saure reinigungsmittel
PL345550A1 (en) Pharmaceutical compositions comprising 2-quinolones
FI935847L (fi) L-DOPA-esterikoostumukset
FI955851L (fi) Synergistisesti stabiloituja nestemäisiä entsymaattisia koostumuksia
NO983438D0 (no) Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
IL107870A0 (en) Pharmaceutical compositions having antidepressant activity comprising pramipexol
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
DE69421784D1 (de) Kraftstoffzusammensetzungen, und Zusätze dafür
ES2188763T3 (es) Factor del tipo relaxina y metodos y usos del mismo.
DK0460062T3 (da) Huperzin A-analoger
ATE254922T1 (de) Pharmazeutische zusammensetzungen mit antimikrobieller wirkung
ID16361A (id) Komposisi kalsium karbonat yang tahan terhadap asam dan penggunaannya
PT897667E (pt) Composicao para melhorar o pao
ID17875A (id) Komposisi farmasi yang mengandung asam 4-oksobutanoat
BG100248A (bg) Инхибитори на скваленсинтетаза
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.